Cargando…

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax

Myelodysplastic syndromes are characterized by ineffective hematopoiesis in one or more lineages of the bone marrow. They are a group of heterogeneous clonal stem cell malignancies with a high risk to progress to acute myeloid leukemia. Currently, there are no curative FDA-approved medications for m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jehangir, Waqas, Karabachev, Alexander, Jahangir, Taimoor, Umyarova, Elvira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091525/ https://www.ncbi.nlm.nih.gov/pubmed/32231817 http://dx.doi.org/10.1155/2020/9031067

Ejemplares similares

Pulmonary Haemosiderosis Secondary to Hereditary Haemochromatosis; a Case Report
por: Jehangir, Waqas, et al.
Publicado: (2020)

A Rare Case of Myelodysplastic Syndrome with Refractory Thrombocytopenia
por: Jehangir, Waqas, et al.
Publicado: (2015)

Metastatic Malignant Paraganglioma Presenting as a Neck Mass Treated with Radiolabeled Somatostatin Analog
por: Jehangir, Waqas, et al.
Publicado: (2021)

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease
por: Hara, Ryujiro, et al.
Publicado: (2021)

Refractory Autoimmune Cytopenias Treated With Venetoclax
por: Gordon, Max J., et al.
Publicado: (2019)

Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy
por: Pinto, Valeria, et al.
Publicado: (2015)

Magnetic Resonance Myocardial Feature Tracking in Transfusion-Dependent Myelodysplastic Syndrome
por: Alonso-Fernandez-Gatta, Marta, et al.
Publicado: (2021)

Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome
por: Badawi, Maha A., et al.
Publicado: (2010)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor
por: Nautiyal, Kirtan, et al.
Publicado: (2014)

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes
por: Fischer, Melissa A., et al.
Publicado: (2022)

Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: El-Cheikh, Jean, et al.
Publicado: (2023)

Myelodysplastic Syndrome and Autoimmunity: A Case Report of an Unusual Presentation of Myelodysplastic Syndrome
por: Merrill, Andrea L., et al.
Publicado: (2011)

Venetoclax in Previously Treated Waldenström Macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2022)

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
por: Olivieri, Jacopo, et al.
Publicado: (2022)

Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes
por: Koutsavlis, Ioannis
Publicado: (2016)

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
por: Zeidan, Amer M., et al.
Publicado: (2022)

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine
por: Kumode, Takahiro, et al.
Publicado: (2014)

Gingival enlargement in myelodysplastic syndrome
por: George, Navia, et al.
Publicado: (2015)

Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study
por: Ho, P. Joy, et al.
Publicado: (2019)

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle
por: Wang, Xiaobo, et al.
Publicado: (2023)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease
por: Kono, Masashi, et al.
Publicado: (2019)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2021)

Copper deficiency mimicking myelodysplastic syndrome
por: Dalal, Neil, et al.
Publicado: (2015)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
por: Park, Sungwoo, et al.
Publicado: (2023)

Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome
por: Kimura, Masamichi, et al.
Publicado: (2015)

Venetoclax: Various toxicities: case report
Publicado: (2021)

Multiple Xanthogranulomas in an Adult Patient with Myelodysplastic Syndrome
por: Martínez-García, Marta, et al.
Publicado: (2020)

Localized lymphadenopathy with myelodysplastic syndrome associated with tuberculosis
por: Nakaya, Aya, et al.
Publicado: (2019)

Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis
por: Luo, Thomas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8te4irfhr3h6mt43i0o966poop